

General description

Irinotecan is an antineoplastic topoisomerase I inhibitor used in the treatment of colorectal cancer.

INN	Irinotecan
ATC codes	L01CE02
Medicine type	Chemical agent
EML status history	First added in 2015 (TRS 994) for Malignant neoplasm metastasis in large intestine Added in 2021 (TRS 1035) for Malignant neoplasms of kidney, except renal pelvis Added in 2021 (TRS 1035) for Rhabdomyosarcoma primary site
Wikipedia	Irinotecan 
DrugBank	Irinotecan 

Recommendations

Section Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

